S. Richards

发表

N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.

J. Harris, J. Gilmore, C. Wolfe, 2006, Bioorganic & medicinal chemistry letters.

Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.

H. Sham, S. Richards, M. Winn, 2006, Bioorganic & medicinal chemistry letters.

Discovery of XL413, a potent and selective CDC7 inhibitor.

Wei Xu, Charles R. Holst, J. Nuss, 2012, Bioorganic & medicinal chemistry letters.

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

K. Longenecker, J. Segreti, H. Sham, 2006, Journal of medicinal chemistry.

Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production.

A. Souers, S. Richards, B. Szczepankiewicz, 2003, Current medicinal chemistry.

Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists.

S. Richards, S. Fung, Jiahong Wang, 2006, Bioorganic & medicinal chemistry letters.

Prospects for pharmacologic inhibition of hepatic glucose production.

A. Souers, S. Richards, B. Szczepankiewicz, 2003, Current medicinal chemistry.

Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake.

J. Findlay, P. Gallagher, S. Mitchell, 2004, Bioorganic & medicinal chemistry letters.

Discovery of a new class of glucosylceramide synthase inhibitors.

J. Nuss, S. Richards, P. Lamb, 2011, Bioorganic & medicinal chemistry letters.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

K. Ogilvie, J. Nuss, S. Richards, 2012, Journal of medicinal chemistry.

N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.

J. Harris, J. Gilmore, C. Wolfe, 2006, Bioorganic & medicinal chemistry letters.

Thiazolidinedione‐Based Insulin Sensitizers:PPAR‐γ Agonists for the Treatment of Type 2 Diabetes

S. Richards, 2013 .